article Open access
Aducanumab Opinion
Asia Filatova✉, Jonathan T. Grossmana
- aNova Southeastern University College Of Osteopathic Medicine
- ✉Corresponding author
International Journal of Medical Science and Clinical Research Studies2022-08-15 0 citations2 references
Looking for the full paper…
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
Aducanumab (brand name Aduhelm) is the first FDA-approved, pharmacologic treatment for Alzheimer’s disease (AD) but many uncertainties remain regarding both efficacy and safety. Of paramount concern are associated adverse effects including cerebral edema and hemorrhage which prompted a post-approval study. Aside from safety concerns, withdrawal from the market may occur if it fails to demonstrate efficacy as described in pre-approval reports.